Reviewer's report

Title: Cholangio-cellular carcinoma responding on Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) - A Case Report

Version: 1 Date: 1 March 2006

Reviewer: Vittorio Gebbia

Reviewer's report:

General

-----------------------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

This is well written case report on the efficacy of gemcitabine and cetuximab in a male patient with cholangio-cellular carcinoma. It may be useful to publish this paper since it may represent a good suggestion for an hypothetical future trial testing the combination of gemcitabine and cetuximab. However authors must change the conclusion section since non conclusions may be drawn from a single case. Therefore " A combination of cytotoxic chemotherapy with targeted biologicals, like cetuximab, seems to be a safe and efficient way to improve quality of life and survival, as reported in this case of a patient suffering from CCC." should be changed into " this experience may suggest that ......"

-----------------------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

Several typewriting mistakes are present in the text. It should be checked for spelling.

-----------------------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)

What next?: Accept after minor essential revisions

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: No

Declaration of competing interests:

'I declare that I have no competing interests'